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Objective. To compare HIV drug resistance in pregnant women with perinatal HIV (PHIV) and those with nonperinatal HIV
(NPHIV) infection. Methods. We conducted a multisite cohort study of PHIV and NPHIV women from 2000 to 2014. Sample size
was calculated to identify a fourfold increase in antiretroviral (ARV) drug resistance in PHIV women. Continuous variables were
compared using Student’s 𝑡-test and Wilcoxon rank-sum tests. Categorical variables were compared using 𝜒2 and Fisher’s exact
tests. Univariate analysis was used to determine factors associated with antiretroviral drug resistance. Results. Forty-one PHIV and
41 NPHIV participants were included. Women with PHIV were more likely to have drug resistance than those with NPHIV ((55%
versus 17%, 𝑝 = 0.03), OR 6.0 (95% CI 1.0–34.8), 𝑝 = 0.05), including multiclass resistance (15% versus 0, 𝑝 = 0.03), and they were
more likely to receive nonstandard ARVs during pregnancy (27% versus 5%, 𝑝 = 0.01). PHIV and NPHIV women had similar rates
of preterm birth (11% versus 28%, 𝑝 = 0.08) and cesarean delivery (47% versus 46%, 𝑝 = 0.9). Two infants born to a single NPHIV
woman acquired HIV infection. Conclusions. PHIV women have a high frequency of HIV drug resistance mutations, leading to
nonstandard ARVs use during pregnancy. Despite nonstandard ARV use during pregnancy, PHIV women did not experience
increased rates of adverse pregnancy outcomes.

1. Introduction
Less than one percent of women living with HIV have perinatally acquired HIV infection (PHIV). According to recent
Centers for Disease Control and Prevention (CDC) HIV
surveillance data, approximately 2,388 PHIV women are

living in the United States [1]. Due to lifelong HIV infection,
many women with PHIV have been exposed to multiple
antiretroviral (ARV) therapy regimens. These exposures may
include inadequate therapy during periods when there were
limited ARV therapy options, such as mono and dual therapy. As a consequence of suboptimal therapy, inconsistent
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drug adherence, and/or prolonged intermittent exposure to
multiple ARV classes, PHIV women may have HIV that has
developed significant drug resistance [2–5].
Antiretroviral drug resistance can limit options for therapy during pregnancy and potentially complicate obstetrical
care for HIV-infected women. PHIV women who have developed ARV drug resistance may require ARV therapies which
are less well studied in pregnancy and may have unknown
toxicities [6, 7]. Potentially secondary to noncompliance or
a suboptimal ARV regimen, PHIV patients may have poor
viral suppression during pregnancy resulting in cesarean
delivery and a higher risk of perinatal transmission [3, 4, 8, 9].
Examples of other risks specific to PHIV pregnant women
include complex psychosocial issues, unplanned pregnancies,
and transmission of HIV to susceptible partners [3, 6, 10, 11].
ARV resistance rates have been reported as high as 30–
50% in PHIV pregnant women [4, 9, 12]. ARV resistance
mutations and drug classes affected are not well described
in previous studies of PHIV pregnant women [4, 9, 12]. The
primary objective of this study was to determine if PHIV
pregnant women are more likely than pregnant women with
nonperinatal HIV infection (NPHIV) to have ARV drug
resistance. We describe the ARV classes affected by HIV
genotypic mutations in both PHIV and NPHIV women. Our
secondary objective is to describe and compare potential
adverse maternal and neonatal outcomes among PHIV and
NPHIV pregnant women.

2. Materials and Methods
The primary objective of this study was to determine how
much more likely PHIV women are to have HIV genotypic
mutations that confer clinically significant ARV resistance
during pregnancy compared to NPHIV women. Prior data
indicated the probability of genotypic resistance to ARVs,
specifically nonnucleoside reverse transcriptase inhibitors
(NNRTIs), in drug naı̈ve NPHIV pregnant women to be
13–17% [13]. Based on previous reports, PHIV women may
have ARV resistance rates as high as 50%. We anticipated a
noncollinear relationship between ARV resistance and timing
of HIV infection. In order to demonstrate odds ratio of
at least 4.0 (13% × 4 = 52%) for ARV resistance in PHIV
pregnant women relative to NPHIV women, 41 cases (PHIV)
and 41 controls (NPHIV) were required to reject the null
hypothesis that this odds ratio equals one with a probability
of 0.8. The Type I error probability associated with this test of
the null hypothesis was 0.05. The study was not powered to
determine differences in pregnancy outcomes between PHIV
and NPHIV.
Because PHIV is a rare condition in pregnancy, a multisite, retrospective cohort study was conducted to enroll
the necessary sample size of PHIV participants. To identify
potential study sites, an email was sent to all providers
participating in the Reproductive Infectious Diseases listserv
(ReproIDHIV Listserv) [14]. Collaborators from twenty-two
sites responded with interest and were provided a copy of
the protocol. Seven sites at academic medical centers in
British Columbia, California, Colorado, Missouri, New York,
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Pennsylvania, and South Carolina elected to participate and
the study protocol was approved by the institutional review
boards at each site (IRB #13184). The study was supported by
the departmental resources of the investigators.
Pregnant women with PHIV who received prenatal care
at any of the study sites from 2000 to 2014 were eligible
for participation. A woman was considered to have PHIV
if her HIV serostatus was confirmed and determined to
be acquired from her biological, serostatus-confirmed HIVinfected mother in the absence of any other risk factors (i.e.,
blood transfusion). Investigators at all 7 sites were responsible for identifying PHIV women for the study. Control
participants were identified as pregnant women with NPHIV
receiving prenatal care during the study period at any study
site. A woman was considered to have NPHIV if she was
diagnosed with HIV at ≥ 11 years of age in the absence
of questionable perinatal infection (HIV-infected mother)
or other risk factors for childhood infection (breastfeeding
from an HIV-infected mother or blood transfusion). NPHIV
participants were selected based on a similar age to study
participants (±1 year of age). Participants were age-matched
in order to reduce an uneven distribution of age-related
medical comorbidities, such as preexisting hypertension and
diabetes, which may potentially impact pregnancy outcomes.
The majority of NPHIV were identified by the Principal
Investigator from one academic institution.
The medical records of participants were reviewed by site
specific investigators to obtain data from maternal antepartum, intrapartum, and postpartum care. Variables of interest
were collected for all participants when available. Maternal
variables included age, race, ethnicity, marital status, insurer,
current partner’s HIV status, history of opportunistic infections, existing medical and psychiatric diagnoses, gestational
age at entry into prenatal care and at delivery, HIV RNA
viral load (copies/mL) and CD4 cell count (cells/mm3 ) at
entry into prenatal care and at delivery, ARV regimens before,
during, and after pregnancy, HIV genotypic mutations associated with clinical drug resistance, evidence of sexually
transmitted infections ((STIs): Neisseria gonorrhea, Chlamydia trachomatis, Trichomonas vaginalis, Treponema pallidum,
human papilloma virus, hepatitis B and C, and herpes
simplex virus), number of prenatal visits, antepartum complications, intrapartum prophylaxis IV zidovudine (AZT)
when indicated, mode of delivery, postpartum infections
including chorioamnionitis, and birth outcomes (e.g., live
birth, intrauterine fetal demise, and spontaneous or elective
abortion). Maternal antepartum complications of interest
were hypertensive disorders of pregnancy, diabetes, maternal
infection(s), preterm labor, anemia, and fetal anomaly and/or
aneuploidy. In participants who gave birth to a live infant,
data were collected from neonatal records up to 18 months
of age. Variables of interest included birth weight, Apgar
scores, level of nursery admit, neonatal postexposure ARV
prophylaxis, duration of ARV prophylaxis, and HIV status.
Neonates were considered HIV-infected if at least two positive HIV DNA PCR tests were confirmed before 18 months of
age [15]. To protect confidentiality, all participants’ data were
deidentified.
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Table 1: Maternal characteristics of pregnant women with perinatal and nonperinatal HIV infection.

Mean age, (years)
Black/African American
Hispanic/Latino
Mean years living with HIV infection
Current HIV-infected sexual partner
Parity
History of sexually transmitted infection(s) (STI)
History of abnormal pap smear
Hepatitis B and/or C coinfection
History of opportunistic infection(s)
History of a psychiatric illness, including depression
Medical comorbiditya
STI diagnosis during pregnancy

Perinatal HIV (𝑛 = 41)
20.9 (±3.2)
21 (51%)
5 (12%)
20.5 (±3.5)
1/24 (4%)
0 (0-1)
22 (51%)
17/37 (46%)
2 (5%)
7/40 (18%)
20/40 (50%)
12 (29%)
5 (13%)

Nonperinatal HIV (𝑛 = 41)
21.7 (±3.1)
29 (71%)
4 (10%)
2.4 (±2.8)
7/22 (32%)
1 (0–2)
25 (61%)
8/38 (21%)
3 (8%)
0
11 (27%)
19 (46%)
11 (27%)

𝑝 value
0.2
0.07
1.0
<0.0001
0.02
0.0004
0.5
0.02
0.7
0.03
0.11
0.11

All denominators are 𝑛 = 41 unless otherwise stated. Continuous variables are represented as means (±standard deviation) and medians (interquartile range).
Continuous variables are compared using Student’s 𝑡-test for means, pooled for equal variances and Wilcoxon rank-sum tests are used to compare medians.
Medical comorbidities excluding HIV, hepatitis, and psychiatric illness, including hypertensive disorders, asthma, anemia, cholelithiasis, transaminitis, obesity,
and neuropathya .

Study site investigators collected and managed data using
REDCap (Research Electronic Data Capture), a secure,
web-based application designed to support data capture
[16]. Statistical analysis was performed using SAS 9.4
software (Cary, N.C.). Continuous variables were compared
using Student’s 𝑡-test (means) and Wilcoxon rank-sum tests
(medians). Continuous variables were tested for normality,
and medians were compared when data were not normally
distributed. Categorical variables were compared using 𝜒2
and Fischer’s exact tests. Univariate logistic regression was
used to determine factors associated with the presence of
ARV drug resistance.

17 MUSC
9 Drexel
5 UBC
41 PHIV

4 Colorado
3 UCSF

82
subjects

2 Rochester
1 Washington
26 MUSC
41 NPHIV

9 Drexel
4 Colorado
2 Rochester

3. Results
As determined by the sample size calculation, 41 PHIV and 41
NPHIV women were included in the analysis (Figure 1). The
mean age of participants at the time of pregnancy was 21 years
(standard deviation (SD) ± 3) with a range of 14–30 years.
The median parity of women was one (interquartile range
(IQR), 0-1). The median gestational age at which women
presented for prenatal care was 11 weeks (IQR, 7–14 weeks),
and the mean number of prenatal visits prior to delivery was
10 (SD ± 5). The HIV status of the participants’ male partner
was recorded in approximately half of the women. NPHIV
women were more likely to report an HIV-infected sexual
partner(s) than PHIV women (32% versus 4%, 𝑝 = 0.02).
When comparing PHIV and NPHIV women, there were no
differences in race, ethnicity, age, and prenatal care initiation
or duration. NPHIV women were more likely to be parous
than PHIV women (1 (IQR 0–4) versus 0 (IQR 0–2), 𝑝 =
0.0004), and PHIV women were more likely to have a history
of abnormal cervical cytology (50% versus 27%, 𝑝 = 0.03).
All pregnancies were singleton gestations (Tables 1 and 2).
The mean duration of known HIV infection for PHIV
women was 21 (SD ± 4) years and it was 2 (SD ± 3) years

Figure 1: Site recruitment of pregnant women with perinatal and
nonperinatal HIV infection. Site key: MUSC, Medical University of
South Carolina, Charleston, SC; Drexel, Drexel University, Philadelphia, PA; UBC, University of British Columbia, Vancouver, BC;
Colorado, University of Colorado, Aurora, CO; UCSF, University of
California San Francisco, San Francisco, CA; Rochester, University
of Rochester, Rochester, NY; Washington, Washington University,
Saint Louis, MO.

for NPHIV women (𝑝 < 0.0001). Of the participants with
NPHIV infection, 21 were diagnosed with HIV within one
year of pregnancy and 20 were known to have HIV of duration of more than one year. Forty-three percent of all participants (36/82) reported current ARV use at initial presentation
for prenatal care. PHIV women were more likely to report
taking ARVs at presentation (68% versus 23%, 𝑝 = 0.006).
Although only 27 PHIV women were on ARVs at conception,
all PHIV women in this study were exposed to ARVs during
their lifetime prior to enrollment. The specific ARV regimens
prescribed to individual subjects throughout their lives prior
to enrollment in this study are not available for inclusion in
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Table 2: Antepartum, intrapartum, and neonatal findings among pregnant women with perinatal HIV and nonperinatal HIV infection.

Perinatal HIV (𝑛 = 41)
Antepartum
11 (6–14)
Gestational age in weeks at initial obstetric visita
ARV use at time of conception
27 (68%)
Initial HIV RNA viral load (copies/mL) in pregnancy
19,945 (99–20,915)
426 (±271)
Initial CD4 cell count (cells/mm3 ) in pregnancy
Number of obstetric visits prior to delivery
10.4 (±5.2)
17/38 (45%)
Pregnancy complicationsb
ARV use during pregnancy prior to delivery
41 (100%)
Intrapartum and postpartum
Gestational age at delivery
38 (38-39)
Preterm delivery (<37 weeks)
4/37 (11%)
HIV RNA viral load (copies/mL) at delivery
40 (0–2,500)
HIV RNA viral load > 1,000 copies/mL at delivery
10 (26%)
HIV RNA viral load < 40 copies/mL at delivery
23 (56%)
484 (265–612)
CD4 cell count (cells/mm3 ) at deliverya
11 (27%)
CD4 cell count (cells/mm3 ) below 200 at delivery
IV AZT administered at least 3 hours prior to delivery when indicated
28/35 (80%)
Cesarean delivery
18/38 (47%)
Any maternal intrapartum or postpartum infection
5/37 (14%)
Neonatal
Live birth
37/38 (97%)
3,065 (2,659–3,370)
Birth weight (gm)a
Low birth weight (<2,500 gm)
8/37 (22%)
NICU admission
5/35 (14%)
Duration of postexposure prophylaxis with oral AZT (weeks)
6 (6)
Perinatal HIV infection
0/30

Nonperinatal HIV (𝑛 = 41)

𝑝 value

11 (8–18)
9 (23%)
4,800 (41–19,047)
516 (±212)
9.9 (±5.3)
24 (59%)
38 (93%)

0.2
<0.0001
0.8
0.1
0.7
0.2
0.2

38 (34–39)
11/39 (28%)
0 (0–1,680)
11 (28%)
26 (63%)
514 (373–646)
4 (10%)
31/37 (84%)
18/39 (46%)
7/38 (18%)

0.4
0.08
0.3
0.9
0.5
0.2
0.08
0.7
0.9
0.6

39/40 (98%)
2,742 (2,435–3,200)
13/38 (34%)
10/35 (29%)
6 (6)
2/32 (6%)

1.0
0.02
0.2
0.2
0.6
0.5

All denominators are 𝑛 = 41 unless otherwise stated. Continuous variables are represented as means (±standard deviation) and medians (interquartile range).
Continuous variables are compared using Wilcoxon rank-sum tests to compare medians (Monte Carlo estimates were used to compare some mediansa ) and
pooled Student’s 𝑡-test is used for means. Pregnancy complications included hyperemesis gravidarum, urinary tract infection/pyelonephritis, hypertensive
disorders of pregnancy, cervical incompetence, threatened preterm labor, abruption, preterm birth (<37 weeks), preterm rupture of membranes, and anemiab .

this study. Of the NPHIV participants with HIV diagnosis
greater than one year, only 30% reported current ARV use at
initial presentation for prenatal care. The median HIV RNA
viral load (copies/mL) and mean CD4 cell count (cells/mm3 )
collected within three months of the initial prenatal visit
were not significantly different between PHIV and NPHIV
women. Of the women reporting ARV use at their initial
pregnancy visit, PHIV women were more likely than NPHIV
women to have HIV RNA viral load ≥ 1,000 copies/mL (46%
versus 0, 𝑝 = 0.01) (Tables 1 and 2).
Over half of participants (24 PHIV and 25 NPHIV) had
an HIV RNA viral load ≥ 1,000 copies/mL at their initial
prenatal evaluation. When using an HIV RNA viral load ≥
1,000 copies/mL as criteria for collecting a genotype (HIV-1
genotype, ViroSeq, ARUP laboratories, Salt Lake City, UT),
60% of participants would have been eligible for genotypic
testing for HIV drug resistance. Not all participants who were
eligible for resistance testing had a genotype collected within
three months of their initial pregnancy visit. Collection of
an HIV genotype during this time period was reported in
34 (42%) participants. Although similar numbers of PHIV

and NPHIV women met criteria for resistance evaluation by
genotype (24 PHIV and 25 NPHIV), PHIV participants were
more likely to have genotypic testing collected within three
months of their initial pregnancy visit compared to NPHIV
counterparts (22 PHIV (54%) and 12 NPHIV (29%), 𝑝 =
0.03). When accounting for genotype collection within three
months of presentation for prenatal care, 55% PHIV versus
17% NPHIV had drug resistance (𝑝 = 0.03) (Figure 2).
In addition to genotype resistance noted in 12 PHIV and
two NPHIV women within three months of initial prenatal
care, ARV drug resistance was documented for seven additional participants either before pregnancy or during pregnancy. ARV drug resistance was documented in 21 participants (17 PHIV and four NPHIV), but 18 resistance patterns
were available for analysis (15 PHIV and 3 NPHIV participants). Drug resistance to the NNRTI class was the most common mutation for both groups. Multiclass ARV drug resistance, resistance to more than one ARV class, occurred exclusively in PHIV women (16% versus 0, 𝑝 = 0.03). Genotypic
resistance to multiple ARV drug classes was documented in
6 PHIV women (NRTIs 𝑛 = 6, NNRTIs 𝑛 = 11, and protease
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60%
61%

HIV RNA
VL > 1,000

71%

Genotype
collected
∗

5

44%
63%

ARV resistance

11%

p = 0.03

15%

Multiclass
ARV resistance 0%

29%

Antepartum
ARV change

21%

Postpartum
ARV change

22%
36%
0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

PHIV
NPHIV

Figure 2: Antiretroviral drug resistance testing and therapy changes
in women with perinatal and nonperinatal HIV infection. The
proportion of women with a genotype collected and ARV resistance
accounts for the number of participants eligible to have a genotype
evaluated (HIV RNA viral load > 1,000 copies/mL). ∗ ARV resistance
and multidrug resistance rates were significantly different between
groups.

inhibitors (PIs) 𝑛 = 6). NPHIV women had resistance to
NRTI (𝑛 = 1) and NNRTIs (𝑛 = 2), but no PIs resistance
was noted. ARV regimens were adjusted during pregnancy in
seven women (five PHIV and two NPHIV) secondary to drug
resistance (Table 3).
Univariate analysis was performed to identify which
maternal factors were associated with the ARV resistance
mutations. Among women who had an HIV genotype collected, PHIV infection was associated with an increased
risk of drug resistance (OR 6.0 (95% CI, 1.03–34.8), 𝑝 =
0.05). PHIV infection was the only variable with a statistically significant association to ARV drug resistance. Other
variables analyzed were the duration of HIV infection prior
to pregnancy, elevated HIV viral load at presentation for
pregnancy, medical comorbidities, race/ethnicity, history of
psychiatric illness, and maternal age.
The majority of participants had documented ARV use
during pregnancy (100% PHIV and 93% NPHIV, 𝑝 = 0.24)
(Table 2). PHIV women were more likely to take integrase
inhibitors (20% versus 2%, 𝑝 = 0.03). Fusion inhibitors (𝑛 =
3) and CCR5 antagonists (𝑛 = 1) were used exclusively in
PHIV women. Resistance testing and results for these alternative drug classes were not available for analysis. At the time
of delivery, there was no significant difference in the number
of women from either group taking NRTIs, NNRTIs, and PIs
(Table 3). An appendix in Supplementary Material available
online at http://dx.doi.org/10.1155/2016/4897501 which provides a detailed description of the types of ARVs prescribed

before, during, and after pregnancy for all study participants
is available upon request.
Medical and psychiatric illnesses were common among
study participants. Psychiatric illness was more common in
women with PHIV (50% PHIV versus 27% NPHIV, 𝑝 =
0.03). Depression was the most common psychiatric diagnosis, affecting 43% of PHIV and 22% of NPHIV women.
NPHIV and PHIV women had similarly high rates of medical
comorbidities in pregnancy (46% NPHIV versus 29% PHIV,
𝑝 = 0.1). The most common medical comorbidities reported
were asthma, obesity, chronic hypertension, and anemia.
Only PHIV women had prior history of opportunistic infection(s). Rates of STIs were similar between PHIV and NPHIV
women (𝑝 = 0.1). The following STIs were common among
participants in both groups: genital herpes (68%), T. vaginalis (22%), C. trachomatis (14%), and N. gonorrhoeae (3%).
Chronic hepatitis was infrequent among participants (6%);
three women had hepatitis B and two had hepatitis C. Both
groups had similar rates of pregnancy-related complications
(45% versus 59%, 𝑝 = 0.2). The most common complications
of pregnancy were hypertensive disorders of pregnancy
(12%), preterm labor/shortened cervical length/preterm
delivery (20%), and premature rupture of membranes (2%)
(Tables 1 and 2).
Live birth rates and cesarean delivery rates were similar
among PHIV and NPHIV women ((97% PHIV versus 98%
NPHIV, 𝑝 = 1.0) and (47% PHIV versus 46% NPHIV, 𝑝 =
0.9), resp.). At the time of delivery, the proportions of
participants with HIV RNA viral load ≥ 1,000 copies/mL and
HIV RNA viral loads below the level of detection (<40 copies/
mL) were similar between groups ((26% PHIV versus 28%
NPHIV, 𝑝 = 0.9) and (56% PHIV versus 63% NPHIV, 𝑝 =
0.5), resp.). The difference in the proportion of participants
with HIV RNA viral loads between 40 and 999 copies/mL
near delivery was not statistically significant (18% PHIV and
9% NPHIV, 𝑝 = 0.18). Similar proportions of participants
received at least three hours of intrapartum IV AZT when
indicated (80% versus 84%, = 0.7) (Table 2).
The median gestational age at the time of delivery was 38
weeks in both groups. Preterm birth (<37 weeks gestation)
rates were not significantly different between groups (11%
PHIV versus 28% NPHIV, 𝑝 = 0.08). Median birth weights
were lower in the NPHIV women (2,742 (IQR 2,435–3,200)
versus 3,065 (IQR 2,659–3,370), 𝑝 = 0.02), but the proportion
of low birth weight (<2,500 gm) infants was similar (34%
NPHIV versus 22% PHIV, 𝑝 = 0.2). Neonatal intensive
care unit admissions were not significantly different between
groups (29% NPHIV versus 14% PHIV, 𝑝 = 0.2). The median
duration of neonatal postexposure AZT prophylaxis was six
weeks for both groups. HIV perinatal transmission was documented among two infants (2/32, 6%) born to a single NPHIV
mother one year apart. The mother did not have prenatal care
and did not take ARVs during either pregnancy. Both infants
were born preterm, one by spontaneous vaginal delivery
complicated by previable premature rupture of membranes
and chorioamnionitis and the other by emergent cesarean
delivery in the setting of abruption and preeclampsia. There
were no documented cases of HIV perinatal transmission
among women with PHIV (Table 2).
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Table 3: Antiretroviral drug resistance patterns in HIV-infected pregnant women.

Subject
number
PHIV 𝑛 = 15

NRTI
resistance

NNRTI
resistance

PI resistance

ARV regimen change
during pregnancy

𝑁=6

𝑁 = 11

𝑁=6

𝑁=5

✓

1

✓

3
5

✓

✓
✓

12

✓

✓

✓

FTC/TDF, LPV/RIT
ABC/AZT/3TC

✓

✓

16

AZT/3TC, DDI, NVP, NFV
FTC/TDF, DRV, RIT

✓

10

28

✓

ART prior to delivery

FTC/TDF, DRV, RIT, T-20
FTC/TDF, LPV/RIT

✓

ABC/3TC, EFV, DRV, RIT

29

✓

ABC, TDF, LPV/RIT

46

✓

FTC/TDF, RAL

✓

50
58

✓

✓

ATZ/3TC, LOP/RIT

✓

ETV, DRV, RIT, RAL

60

✓

✓

77

✓

✓

FTC/TDF, EVG, COB

78

✓

✓

DRV, RIT, RAL, ETV

𝑁=1

𝑁=2

18

✓

25

✓

56

✓

✓

79
NPHIV 𝑛 = 3

✓

TPV, RIT, MVC, T-20, DTG

DRV, RIT, FTC/TDF, ABC/3TC
𝑁=0

✓

𝑁=2
AZT/3TC, LPV/RIT
✓

AZT/3TC, RAL
AZT/3TC, NFV

The genotypic mutation types were not recorded for 3 subjects: 2 PHIV (#80 and 81) and 1 NPHIV (#76). The ART regimens at delivery for these subjects were
#80, FTC/TDF/RPV; #81, FTC/ETC/EVG/COB; and #76, ABC/3TC, ETV. #76 required a change in ART during pregnancy. ART, antiretroviral therapy; NRTI,
nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; 3TC, lamivudine; ABC, abacavir; ATV,
atazanavir; COB, cobicistat; DRV, darunavir; DTG, dolutegravir; EFV, efavirenz; ETV, etravirine; EVG, elvitegravir; FTC, emtricitabine; LPV, lopinavir; MVC,
maraviroc; NFV, nelfinavir; NVP, nevirapine; TDF, tenofovir; RAL, raltegravir; RIT, ritonavir, RPV, rilpivirine; T-20, enfuvirtide.

4. Conclusions
HIV genotypic patterns suggestive of clinically relevant
ARV drug resistance were documented in PHIV pregnant
women three times more frequently than NPHIV pregnant
women. Previous studies have documented clinically relevant
genotypic mutations in 30–50% of PHIV pregnant women
and in 13–17% of NPHIV pregnant women [4, 9, 12]. We
anticipated and found comparatively higher rates of ARV
drug resistance among PHIV women likely due to their
lifelong HIV infection and potential intermittent exposure
to multiple ARV classes and suboptimal ARV regimens.
Providers caring for HIV-infected pregnant women should be
aware of the potential for high rates of ARV resistance among
all pregnant women in this age group but especially among
women born with HIV infection.
Compared to previous studies, we were able to document
the patterns of HIV drug resistance in PHIV pregnant
women. The genotypic resistance in NPHIV women was
limited to the NRTI and NNRTI classes compared to multiple
ARV classes in PHIV women. Six PHIV women had multidrug resistant HIV infection, and one PHIV women had
resistance mutations to all three major ARV classes (NRTI,

NNRTIs, and PIs). Due to multidrug resistance, PHIV
women were more likely to be prescribed ARV combinations
that are nonstandard regimens for the prevention of perinatal transmission [15]. During the study period, nonstandard ARV therapies prescribed for PHIV pregnant women
included integrase inhibitors, fusion inhibitors, and CCR5
antagonists. Given the importance of HIV viral suppression
during pregnancy, providers caring for pregnant women
with PHIV should be familiar with the potential use and
limitations of these alternative ARVs during pregnancy.
Our findings of high rates of ARV drug resistance support
the recommendation for HIV genotype analysis in early pregnancy. Genotypic testing should be collected and assessed as
early as possible in all HIV-infected women [15]. These tests
should be repeated during later pregnancy in women with
poorly suppressed HIV RNA viral loads. When resistance
to standard ARV classes used for prevention of perinatal
transmission is suspected, providers should consider alternative drug classes and order additional resistance testing for
integrase inhibitors, fusion inhibitors, or CCR5 antagonists.
PHIV women were more likely to report ARV use at the
time of pregnancy diagnosis, but overall use of ARVs prior
to conception was low. Only 68% of PHIV women and even
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fewer NPHIV women (23%) were on ARV therapy at initial
presentation for pregnancy care. Only 30% of NPHIV women
diagnosed with HIV at least one year prior to pregnancy
reported ARV use at presentation for care. In previous
studies, PHIV women were more likely to have poor viral
suppression during pregnancy, likely due to inconsistent drug
adherence [3–5, 8]. In contrast to these reports, PHIV women
in our study had similar rates of virological suppression
and comparable CD4 cell counts to NPHIV women during
pregnancy. Providers caring for reproductive age women with
HIV infection should be aware of their pregnancy intentions
in order to reduce the risk of perinatal HIV transmission from
delayed exposure to effective ARV therapy before and during
pregnancy. Women currently not seeking pregnancy should
be offered effective contraception [17].
Although the reduction of perinatal transmission is a
primary objective of prenatal care for HIV-infected women,
pregnancy is also a time when HIV-infected women are
examined frequently and can be screened for other significant medical comorbidities. Current or past psychiatric
illness, especially depression, was more common among
PHIV women (50%). Given the potential effects of depression on pregnancy, HIV-infected women should receive a
multidisciplinary approach including psychiatric evaluation
and support services [10, 18]. Additionally, PHIV women
were more likely to have a history of abnormal pap smears.
Frequent visits during pregnancy can provide adequate time
for evaluation for cervical cancer risks among HIV-infected
women.
Our study revealed that HIV-serodiscordance was very
common among pregnant women and their partners. PHIV
women were more likely to have HIV susceptible partners
(96%) compared to NPHIV women (68%). This difference
is likely explained by NPHIV women potentially having
acquired HIV from their current partners, as compared to
PHIV counterparts, who acquired HIV at birth. Prenatal
providers should be aware of the potential risk of HIV
transmission to HIV susceptible partners during pregnancy.
In an effort to reduce the transmission of HIV to susceptible
partners, providers should provide risk reduction counseling
to all serodiscordant couples and frequent HIV testing of susceptible partners and evaluate partners for HIV preexposure
prophylaxis [19].
The limitations of this study are related to the retrospective cohort design. This study design was necessary given the
relative rarity of the exposure of PHIV in pregnancy. Data
were not available for every variable for every participant.
Genotypic testing was not available for all 82 participants.
This can partially be explained by 33 (40%) women having
HIV RNA viral loads < 1,000 copies/mL at the time of initial
pregnancy care. It is unclear to the investigators why genotypes were not collected in all 49 women who were eligible for
HIV drug resistance evaluation (HIV RNA viral load ≥ 1,000
copies/mL). Three genotype resistance patterns were not
available for detailed review. Another limitation of our study
is that we neglected planning for and carrying out collection
of information regarding substance use, including tobacco,
alcohol, and prescription and/or street drugs. A prospective
study design and inclusion of all PHIV and NPHIV women
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presenting to any site during the study period would be the
most effective means for evaluating the primary outcome and
potential differences in pregnancy outcomes. However, given
the rarity of PHIV during pregnancy, a prospective, multisite
study would exceed the resources available.
The results of this study may not be applicable to all populations. The majority of study participants were identified
at an academic center in the Southeast, where the Principal
Investigator practices. According to the CDC, the Southeast
has the 2nd highest prevalence of HIV infection in the United
States. As of 2011, the Southeast had the highest number of
new HIV infections and the largest proportion of individuals
living with stage 3 HIV/AIDS [1]. Perinatal transmission rates
are also high in this region [1]. Due to the increased rate of
perinatal HIV transmissions, it is reasonable that the majority
of cases and controls are clustered in this region due to
prevalence of infection. However, the entirety of PHIV cases
were distributed from multiple locations in North America
suggesting this data has generalizability for many centers
caring for PHIV women during pregnancy.
This is the largest single group of PHIV women studied
in comparison to age-matched NPHIV controls. This study
adds to the medical literature by describing the types of HIV
ARV mutations that affect the care of HIV-infected women
during pregnancy. Based upon the data presented here,
obstetric providers of PHIV and NPHIV women should have
a high suspicion for clinically relevant HIV drug resistance
early in pregnancy in order to best select effective therapies
for the prevention of perinatal HIV transmission. Lastly,
PHIV women did not experience higher rates of perinatal
complications and there were no perinatal HIV transmissions to PHIV-exposed infants. Although not powered to
identify any significant differences in pregnancy outcomes,
our findings suggest that PHIV women may have similar
pregnancy outcomes compared to NPHIV. Further investigation is needed, but providers can offer some reassurance
to women living with PHIV infection that they are likely to
have pregnancy outcomes comparable to other HIV-infected
pregnant women.
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